Journal of the European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology
5 years ago

A prospective right–left comparative study to evaluate the efficacy and tolerability of combination of NB-UVB and topical bimatoprost 0.03% eye drops versus NB-UVB given alone in patients of vitiligo vulgaris

Rajsmita Bhattacharjee, Sendhil Kumaran Muthu, Davindar Parsad, Seema Sharma
The treatment of vitiligo has been a tough challenge for dermatologists. Phototherapy, apart from being first line monotherapy,1 has also been used in combination with topical therapies like corticosteroids, khellin, phenylalanine, calcineurin inhibitors etc, with the aim of hastening and enhancing repigmentation and reducing side-effects.2,3 Recent reports have highlighted darkening of iris, and eyelash and periocular hyperpigmentation induced by latanoprost (prostaglandin F2α analogue) used for treatment of glaucoma.4 Extrapolating these findings in treatment of vitiligo, we assessed the outcome of NB- UVB and topical bimatoprost 0.03% combination versus NB-UVB alone in a prospective right–left comparative study. This article is protected by copyright. All rights reserved.

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1111/jdv.14882

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.